SCHEMBL21782363

SCHEMBL21782363

CNc1cc(C)oc1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7504648 0.73 CYP3A4 (0.39)
SCHEMBL5658620 0.72 ALDH1A1 (0.37)
SCHEMBL4470377 0.69 MAPT (0.35)
SCHEMBL2461470 0.68 HSD17B10 (0.42)
SCHEMBL182910 0.65
SCHEMBL17790252 0.64 ALOX5 (0.42)
SCHEMBL10768398 0.63
SCHEMBL755488 0.63
SCHEMBL5082151 0.62 KDM4E (0.36)
SCHEMBL14386111 0.62 MAPT (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114206870-A Tricyclic AKR1C3 dependent KARS inhibitors 诺华股份有限公司 2022-03-18 CN disclosed
EP-2630135-B1 1-(HETEROCYCLIC CARBONYL) PIPERIDINES BAYER IP GMBH (DE) 2020-03-04 EP disclosed
CN-102174024-B 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS INC 2015-02-11 CN disclosed
CN-102174024-A 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS INC 2011-09-07 CN disclosed
CN-1625400-B 2, 4-pyrimidinediamine compounds and uses thereof RIGEL PHARMACEUTICALS INC 2011-04-13 CN disclosed
CN-1678321-A Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS INC (US) 2005-10-05 CN disclosed
CN-1625400-A 2, 4-pyrimidinediamine compounds and uses thereof RIGEL PHARMACEUTICALS INC (US) 2005-06-08 CN disclosed